Status:
COMPLETED
Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Irritable Bowel Syndrome (IBS)
Eligibility:
All Genders
18+ years
Brief Summary
Irritable bowel syndrome (IBS) is a very common chronic functional gastrointestinal disorder characterised by abdominal pain/discomfort, bloating and alterations in bowel function. This condition sign...
Detailed Description
This will be an open-label, single arm post marketing surveillance study involving an active treatment period of a minimum 3-week and a maximum 12-week duration. Treatment with Progut will be at the d...
Eligibility Criteria
Inclusion
- Patients aged 18 and above with IBS diagnosed by the presence of the following symptoms:
- abdominal pain,
- bloating and constipation in whom organic pathology has been excluded
- All patients would have had endoscopy done in the past 3 years to exclude organic lower gastrointestinal pathology.
- All patients would have been prescribed Progut (1-3 capsules per day)by their physicians.
Exclusion
- Women who are pregnant, intending to become pregnant or breastfeeding.
- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
- Immunocompromised patients
- Hypersensitivity to Progut
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00904696
Start Date
May 1 2009
End Date
September 1 2009
Last Update
April 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore, 119074